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Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a g-phos-
phate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves
as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-
directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that
a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical
and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through
recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the
development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues
in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including
prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmaco-
logical specificity throughmutation of the reactive cysteine residue. Here, we review recent efforts to develop
cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the
ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment
of the potential ‘‘kinase cysteinome’’ and discuss strategies for the efficient development of new covalent
inhibitors.Kinases are one of the largest gene families whose function is to
catalyze the transfer of the g-phosphate from ATP to a specific
target molecule bearing nucleophilic hydroxyl or amino groups
including lipids, carbohydrates, and proteins. Protein phosphor-
ylation can induce a myriad of consequences including modula-
tion of enzyme activity, conformation, stability, localization, and
association with other proteins or small molecules (Cohen,
2002). The approximately 530 kinases present in the human
genome have been named the ‘‘kinome’’ and include 420
serine/threonine, 94 tyrosine, 25 atypical, and 49 ‘‘pseudo
kinases’’ that putatively lack the ability to catalyze the phospho-
transfer reaction(Manning et al., 2002a, 2002b). Kinases have
been found to function in virtually every biological process and
pathway and perhaps not surprisingly deregulation of kinase
function through environmental and genetic alterations is a hall-
mark of many pathological conditions (Hanahan and Weinberg,
2011). Since the mid-1980s when v-SRC was initially discovered
to be a tyrosine kinase and capable of functioning as an ‘‘onco-
gene,’’ basic research and clinical investigation have implicated
the deregulation of approximately 180 kinases in diverse
pathology associated with metabolism, development, immu-
nology, cancer, and infectious disease (Hunter and Sefton,
1980). The development of kinase inhibitors has attracted an
enormous amount of drug discovery attention, primarily in the
oncology and inflammatory diseases areas. Currently, approxi-146 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd Amately 40 kinases are actively being pursued as therapeutic
targets, and 14 kinase inhibitors have received regulatory
approval (Barf and Kaptein, 2012; Kontzias et al., 2012). Interest-
ingly, by far the most significant success has been achieved in
oncology by targeting mutationally activated ‘‘oncogenic’’ driver
kinases including Bcr-Abl, EGFR, c-Kit, PDGFR, ALK, and b-RAF
in tumors that are ‘‘addicted’’ to the constitutive activation of
these kinases (Haber et al., 2011).
Currently, the vast majority of protein kinase inhibitors (PKIs)
are reversible ATP competitive inhibitors, which achieve target
selectivity by recognizing unique features of particular ATP-
binding pockets. This class of inhibitor typically occupies the
adenine-binding region of the ATP-binding pocket and extends
into surrounding regions not occupied by ATP, and inhibitor
binding often induces dramatic conformational rearrangements
to the pocket. Compounds that bind to the ATP-binding site
with the kinase assuming an active conformation, or a conforma-
tion otherwise conducive to ATP binding, are called ‘‘type I’’
inhibitors while those that induce a ‘‘flip’’ of the DFG motif that
marks the start of the activation loop are called ‘‘type II’’ (Liu
and Gray, 2006). Multiple other examples of ‘‘induced fit’’ have
been observed providing clear evidence for the plasticity of the
ATP-binding pocket (Changeux and Edelstein, 2011). However,
given the high sequence conservation of the ATP-binding site
and the very large number of kinases, achieving a high degreell rights reserved
Figure 1. Electrophiles Used in Irreversible Kinase Inhibitors
Black balls represent other pharmacophore structures.
Chemistry & Biology
Reviewof kinase selectivity has proved extremely challenging. While
there are some examples of exquisitely selective kinase ATP-
competitive inhibitors such as lapatinib, which targets Her2,
and SB239063, which targets p38 kinase, most inhibitors have
a spectrum of targets that widens as inhibitor concentration
increases (Rusnak et al., 2001; Underwood et al., 2000). There
have been tremendous advances in our ability tomeasure kinase
inhibitor selectivity across near-comprehensive panels using
biochemical kinase assays, competition binding assays, and
chemical proteomic approaches (Karaman et al., 2008; Liu
et al., 2012b; Okerberg et al., 2005). These efforts have enabled
both prospective and retrospective matching of compounds
with targets and have greatly furthered our understanding of
the mechanism of action of a number of inhibitors.
The majority of new kinase inhibitors are being developed in
the pharmaceutical sector typically targeting kinases that
have been intensively investigated previously in academia. The
requirement for significant prevalidation of potential kinase
targets prior to the development of inhibitors in the pharmaceu-
tical sector has resulted in a shortage of inhibitors targeting the
kinases whose biological function have received less attention.
Therefore, new approaches are needed for the rapid generation
of inhibitors of poorly understood kinases that can be used as
pharmacological probes of mechanism. Covalent kinase inhibi-
tors provide an ideal platform for this endeavor as we discuss
further below.
Covalent kinase inhibitors have typically been developed by
structure-guided incorporation of an electrophilic moiety into
an inhibitor that already possesses submicromolar binding
affinity to the target of interest (Potashman and Duggan, 2009).
The majority of covalent inhibitors have been designed to target
the highly nucleophilic thiol group of cysteine residues (Leproult
et al., 2011). While a large number of kinases have cysteine resi-
dues in and around the ATP-binding site, there are no cysteine
residues that are conserved among kinases that serve a key
catalytic function to our knowledge. Covalent inhibitors will
initially bind noncovalently, and then, if the trajectory of the reac-
tive moiety is appropriate, covalent bond formation will take
place, permanently disabling enzymatic activity. Kinase function
is only restored following expression of new protein, the kinetics
of which can vary dramatically for different kinases. One major
advantage of covalent kinase inhibitors is that high selectivity
for a given target kinase can be obtained using a combination
of both noncovalent and covalent binding. An irreversible inhib-Chemistry & Biologitor that has one dominant binding mode will typically only form
a covalent bond with a kinase that possesses a cysteine at
a particular position in the ATP-binding site. Therefore, noncova-
lent recognition only needs to enable discrimination between
kinases that possess an equivalently placed cysteine residue.
Cysteine residues possess an aliphatic thiol (SH), which has
unique reactivity among the naturally occurring amino acids.
For example, the deprotonated thiolate anion is a potent
nucleophile that is exploited as the key catalytic residue in phos-
phatases and cysteine proteases. Cysteines also serve key non-
catalytic functions such as stabilizing protein tertiary structure
through formation of disulphide crosslinks and coordination of
enzyme cofactors such as metals (Jacob et al., 2012). Cysteine
residues can be targeted by numerous posttranslational modifi-
cations including S-nitrosylation, S-prenylation, and oxidation to
sulfenic and sulfonic acids (Chalker et al., 2009). Most covalent
inhibition strategies that have been explored to date target the
highly nucleophilic cysteine thiolate.
A number of electrophilic ‘‘warheads’’ that can react with
nucleophiles such as cysteine, lysine, or tyrosine have been
explored in the design of irreversible kinase inhibitors. The
Michael addition reaction is the most widely utilized reaction to
achieve irreversible binding. Functional groups typically intro-
duced to undergo this addition reaction include acrylamides,
vinyl sulfonates, quinones, alkynyl amides, and propargylic
acid derivatives (Figure 1). A second frequently employed chem-
istry uses nucleophilic displacement or addition to a-halo
ketones, thiocyanates, alkynes, nitriles, epoxides, sulfonyl fluo-
ride, and sometimes thiol itself. Electrophiles, such as cyclic
1,3-diketone, have also been developed that specifically react
with sulfenic acids (Leonard et al., 2011). The ability to target
differentially modified cysteine residues may afford further
means of achieving selectivity.
Historically, there has been considerable reluctance by many
organizations to pursue covalent inhibition strategies due to risks
of haptenization, the most studied examples being haptens
generated by reactive metabolites (Uetrecht, 2008). Unfortu-
nately, preclinical or even clinical tests that are reliable predic-
tors of drug safety do not currently exist. Interestingly, a recent
retrospective analysis suggested that idiosyncratic toxicities
have not been observed for any inhibitors administered at doses
of less than 10mg/kg (Nakayama et al., 2009). This suggests that
well-designed and highly potent covalent inhibitors might have
adequate safety profiles. Irreversible inhibitors are widely used
in clinical practice including some of the most important medi-
cines such as the anti-inflammatory drug aspirin and the broad
class of antibacterial beta-lactam antibiotics such as penicillin.
Other widely usedmetabolic activationmechanism-based cova-
lent drugs include the proton pump inhibitor omeprazole and
antiplatelet drug clopidogrel (Potashman and Duggan, 2009).
Although it may be counterintuitive to create selectivity via
a covalent mechanism, the inhibitor electrophilicity can be fine-
tuned such that the reaction only occurs in the target binding
site. Additionally, covalency can also provide extended pharma-
codynamic duration without the need to maintain high levels
of drug to achieve continuous target engagement (Smith et al.,
2009).
Recently, there has been a resurgence of interest in irrevers-
ible inhibitors, and this topic has been excellently reviewed iny 20, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 147
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2011), from a risk-benefit perspective (Barf and Kaptein, 2012;
Johnson et al., 2010), and in terms of the current irreversible
inhibitors that are in preclinical or clinical development (Garuti
et al., 2011; Singh et al., 2010). Leproult et al. (2011) has also
provided a bioinformatic mapping of the potential cysteine con-
taining kinases that could potentially be covalently targeted
based upon available X-ray crystal structures. In this review,
we summarize recent efforts to develop potent and selective irre-
versible PKIs and describe their modes of recognition of the
ATP-binding site and a description of their biological profiles
from the perspective of a medicinal chemist. We also provide
an analysis of the types of approaches that can be employed
to efficiently generate these inhibitors and present a bio-
informatics analysis of the potentially targetable cysteines in
and around the ATP-binding pocket based on a combination of
Pfizer’s in-house and publicly available crystal structures. This
information is complementary to the previously published arti-
cles, and we encourage the interested reader to see these
references for additional information.
Overview of the Currently Developed Irreversible PKIs
Although most recently reported covalent inhibitors are
synthetic, a number of natural products have evolved that cova-
lently modify cysteine residues in kinase ATP-binding sites (Liu
et al., 2012a). One of the most well-characterized classes of
covalent kinase inhibitors are the resorcylic acid lactones
(RALs) with hypothemycin being the most well-known member
(Sonoda et al., 1999). Hypothemycin was originally isolated
based on its antifungal activity, and subsequent investigations
demonstrated it to be a covalent protein kinase inhibitor. Cova-
lent bond formation is achieved through reaction of its base
cis-enone function with cysteine residues (Figure 2). Santi and
co-workers used sequence alignment to identify a conserved
cysteine residue immediately preceding the conserved ‘‘DFG
motif’’ that marks the start of the kinase activation loop that is
present in a number of kinases inhibited by hypothemycin
including MEK1/2, ERK1/2, PDGFRs, FLT3, and VEGFRs
(Schirmer et al., 2006). A cocrystallized structure of ERK2 with
hypothemycin (PDB: 2E14) demonstrated a covalent bond
between Cys166 of ERK2 and the cis-enone moiety of the inhib-
itor (Figure 3A) (Ohori et al., 2007). The phenolic hydroxyl group
of hypothemycin forms two hydrogen bonds with Met108 in the
kinase hinge segment. Two additional hydrogen bonds are
formed between Lys114 in the solvent exposed area and theme-
thoxy group and between Tyr36 located in the P loop with the
hydroxyl group in the marocyclic ring. Several hypothemycin
analogs, including FR148083, LL-Z1640-2, and LL-782277, are
believed to share the same inhibitory mechanism with TAK1
and MEK kinases (Winssinger and Barluenga, 2007). Starting
from hypothemycin, a focused medicinal chemistry effort to
improve its drug-like properties resulted in a variety of analogs
including the structurally similar drug candidate E6201 (Bar-
luenga et al., 2010; Goto et al., 2009; Jogireddy et al., 2009).
E6201 inhibits MEK1 biochemically with a low nanomolar IC50
and exhibits strong anti-inflammatory and antiproliferation
activities. E6201 is currently in phase I clinical trials for advanced
solid tumors and in a phase II trial for psoriasis (Table 1) (Goto
et al., 2009; Muramoto et al., 2010).148 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd AThe development of synthetic irreversible PKIs was initiated at
Parke-Davis and Wyeth (now Pfizer) in the early 1990s with the
goal of targeting EGFR with covalent inhibitors for the treatment
of cancers (Singh et al., 1997; Wissner and Mansour, 2008).
PD168393 was one of the first reported synthetic irreversible
PKIs with a reported IC50 of 2 nM against EGFR and an IC50 of
114 nM against Her2 (Fry et al., 1998). PD168393 is a 4-amino-
quinazoline with an acrylamide electrophile installed at the
6-position designed to target Cys797 located a few residues
C-terminal to the kinase hinge binding region of EGFR.
PD168393 inhibits the proliferation of EGFR and Her2-depen-
dent cell lines A431 and SKBR3 with 95 and 15 nM EC50s,
respectively, while not inhibiting the proliferation of the non-
EGFR and Her-dependent cell line SW620 at concentrations of
up to 4 mM (Tsou et al., 2005). Further development of this scaf-
fold resulted in a number of compounds that advanced to clinical
trials including CI-1033 (clinical development terminated) and
PF-00299804 (phase III trial) (Engelman et al., 2007; Smaill
et al., 2000). Replacement of one of the quinazoline nitrogens
with a nitrile resulted in another set of compounds that advanced
to clinical trials: EKB569 (phase II trial completed), HKI-272
(phase III trial), and BIBW-2992 (phase III trial) (Li et al., 2008;
Yoshimura et al., 2006). All of these compounds target Cys797,
a residue conserved among EGFR, Her2, and Her4, which can
be visualized in the HKI-272-EGFR costructure (PDB: 2JIV).
The costructure suggests that a key hydrogen bond exists
between the quinoline nitrogen and Met793 in the kinase hinge
segment and between Asp855 in the highly conservedDFGmotif
and the pyridine side chain of the inhibitor. A covalent bond is
evident between the N,N-dimethyl-butenoic amide and Cys797
(Figure 2B). HKI-272 exhibits IC50s of 59 and 92 nM for inhibition
of Her2 and EGFR kinase activity, respectively. HKI-272 inhibits
the proliferation of A431 and SKBR3 cells with EC50s of 86 and
118 nM, respectively, while demonstrating selectivity over the
non-EGFR-addicted cell line SW620 (730 nM). Kinome-wide
selectivity profiling using KinomeScan methodology demon-
strated HKI-272 to be a very selective inhibitor: in addition to
EGFR and Her2, it only exhibited potent binding to MAP4K3/5
and MST3/4 (Kd < 10 nM) (Davis et al., 2011). These additional
targets do not appear to have been validated in cellular assays
to date.
Kinase sequence alignment indicates that there are eight non-
EGFR family kinases that also possess a cysteine at the same
position as Cys797 of EGFR. These eight kinases include all
five members of the Tec family of kinases (BMX, BTK, ITK,
TEC, and TXK), one Src family member (BLK), MKKa7, and
JAK3. Not surprisingly, some compounds crossreact with
kinases in this group. PD168393, for example, exhibits a
1.1 mM IC50 against BMX and inhibits BMX-dependent cell
growth in the Ba/F3 cell system with an EC50 of 0.3 mM (Hur
et al., 2008). As discussed further below, more recent efforts
have been expended to develop covalent inhibitors of the Tec
family kinase BTK (Figure 3C).
Despite lung cancer patients that express mutant EGFR (exon
19 deletion or L858R) displaying dramatic responses to first-
generation ATP-competitive inhibitors initially, all patients
relapse after 12–18months (Rosell et al., 2009). In approximately
50%of cases, resistance is the result of mutation of the so-called
gatekeeper residue from a threonine to a methionine (T790M).ll rights reserved
Figure 2. Representative Chemical Structures of Reported Irreversible Protein Kinase Inhibitors
Compounds were listed as reported names; those that do not have generic names are named in the order they are mentioned in the text.
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Km for ATP thereby increasing the concentration of inhibitor
needed to efficiently inhibit signaling (Yun et al., 2007). While
the first-generation covalent inhibitors including CI-1033 and
HKI-272 can inhibit activated alleles of EGFR harboring
T790M, they do so at a concentration 10–100 times higher
than required to inhibit the nongatekeeper mutants. To over-
come this limitation, a second-generation of covalent inhibitor
from the aminopyrimidine class, exemplified by WZ-4002, was
discovered that potently inhibits activated alleles of EGFR
harboring T790M (Zhou et al., 2009). This inhibitor also targets
Cys797 but approaches the thiol group from a different trajectory
relative to the first-generation quinazoline acrylamide inhibitors.Chemistry & BiologInterestingly, an interaction between the chlorine on the pyrimi-
dine of the inhibitors with the methionine gatekeeper, an inter-
action that has been termed a ‘‘halogen bond,’’ results in the
inhibitors possessing selectivity for T790M versus wild-type
EGFR (Figure 3D) (Hernandes et al., 2010). WZ4002 overall
possesses quite good kinase selectivity but does show activity
on some Tec family kinases as expected based on the cysteine
position.
The same 4-aminoquinazoline scaffold present in the first
generation EGFR inhibitors was used by scientists at Wyeth to
develop a covalent inhibitor of the vascular endothelial growth
factor receptor (VEGFR) (compound 1) using a structure-based
design approach (Figure 2) (Wissner et al., 2005). Compound 1y 20, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 149
Figure 3. Representative Binding Modes of Irreversible Protein Kinase Inhibitors
(A) ERK (PDB: 2E14), (B) EGFR (PDB: 2JIV), (C) BMX (modeling-based PDB: 3SXS), (D) EGFR(PDB: 3IKA), (E) VEGFR (modeling-based PDB: 1VR2), (F) RSK2
(modeling-based PDB: 2QR7), (G) BTK (modeling-based PDB: 3GEN), (H) KIT (modeling-based PDB:1T46), (I) JNK (PDB: 3V6S), (J) FGFR (PDB: 2FGI), (K) NEK2
(modeling-based PDB: 2JAV), (L) GSK3-b (modeling-based PDB: 1I09).
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located immediately before the ‘‘DFG’’ motif in VEGFR. Molec-
ular modeling suggests the quinazoline N1 makes the expected
hydrogen bond to the hinge region with additional hydrogen
bonds formed between the inhibitor and Asp1046 and Lys868
(Figure 3E). This irreversible inhibitor exhibited a 50 nM IC50 for
VEGFR. Further elaboration of this compound allowed the
construction of a dual covalent inhibitor of VEGFR and EGFR
(Compound 2) (Wissner et al., 2007). An acrylamide was installed
to target Cys797 in EGFR and the quinone was maintained to
target Cys1045 in VEGFR (Figure 2). The resulting compound
inhibits the kinase activity of EGFR and VEGFR with IC50s of 18
and 102 nM, respectively.
Another successful example of structure-guided covalent
inhibitor design is the development of FMK, a fluoromethyl
ketone derivatized inhibitor of RSK1, 2, 4 (Figure 2) (Cohen
et al., 2005). FMK achieves selectivity for the RSKs by combining
two selectivity filters: the presence of a small gatekeeper amino
acid (residue T493) in Rsk and covalent bond formation with
Cys463 located in the P loop, which resides on the ‘‘roof’’ of
the ATP-binding site. There are only 11 kinases (RSK1,2,3,
MSK1,2, PLK1,2,3,4, NEK2, andMEKK1) that possess a cysteine150 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd Aat the same position as Cys463 in Rsk, and all of these kinases
have a larger gatekeeper amino acid. FMK inhibits Rsk kinase
activity with an IC50 of 15 nM. Molecular modeling indicates
that the pyrollopyrimidine core forms two hydrogen bonds in
the hinge binding area with Met496 and Glu494 (Figure 3F). In
addition, a hydrogen bond is predicted to exist between the
exocyclic amino group and gatekeeper residue Thr494. The
hydroxyl group in the butenol side chain forms a hydrogen
bond with Asn544 that helps to fix the binding conformation. A
biotin-labeled FMK probe was capable of efficiently purifying
only RSK1 and RSK2 from HEK293 cell at a concentration of
1 mM. The discovery and characterization of FMK provides
a compelling example of the strength of structure-guided design
of highly selective covalent kinase inhibitors.
Another group of kinases that have been successfully targeted
by covalent inhibitors are the TEC family kinase and include TEC,
ITK, TXK, BMX, and BTK. These kinases possess a cysteine in an
identical location to Cys797 of EGFR. Researchers at Pharmacy-
clics developed a pyrazolopyrimidine compound, PCI-32765,
that is a highly potent inhibitor of BTK (Honigberg et al., 2010).
Molecular modeling predicts that the aminopyrazolopyrimidine
forms three hydrogen bonds in the hinge area with Met477,ll rights reserved
Table 1. Summary of Clinically Developed Irreversible Kinase Inhibitors
Drug Name Primary Target Activity IC50(nM) Warhead Active Site Clinical Stage Developer
HKI-272 EGFR/Her2 59/92 Acrylamide C797 Phase III Pfizer, licensed to Puma
BIBW-2992 EGFR/Her2 14 Acrylamide C797 Phase III Boehringer Ingelheim
PF-00299804 Pan-EGFR 15 Acrylamide C797 Phase III Pfizer
CO1686 EGFR/T790M 0.5 Acrylamide C797 Phase II Avila/Clovis
E6201 MEK1 5.2 Enone C297 Phase II EiSai
PCI-32765 BTK 0.46 Acrylamide C481 Phase III Pharmacyclics
AVL-292 BTK 0.5 Acrylamide C481 Phase I Avila/Celgene
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directed to the inner hydrophobic pocket, analogous to the
binding mode of FMK. A water-bridged trihydrogen bond
between Cys481, Asn484, and PCI-32761 also helps to fix the
binding conformation. The acrylamide electrophile forms a
covalent bond with Cys481. PCI-32765 inhibits BTK activity
with an IC50 of 0.5 nM and is also inhibitory toward several other
protein kinases, including BLK, BMX, EGFR, Her2, ITK, JAK3,
and TEC, that contain an analogous cysteine, but PCI-32765
does not show activity against most other protein kinases.
PCI-32765 is currently in phase II clinical trials for various
B-cell-related lymphomas such as DLBCL, MCL, and INHL. A
compound (AVL-292, structure not disclosed) developed by
Avila therapeutics (now Celgene) is believed to share the cova-
lent mechanism as PCI-32765 and is currently in phase I clinical
trials for NHL and CLL.
Researchers from Pfizer recently reported the development of
the first covalent inhibitors of ITK derived from a privileged ATP-
site-directed pyrazolopyrimidine (compound 3) (Zapf et al.,
2012). Starting from an acrylamide-containing screening ‘‘hit,’’
structure-based design was used to guide the development of
a potent inhibitor that was active at nanomolar concentration in
whole blood and that effectively silenced T cell receptor
signaling for 24 hr.
A dual c-KIT/PDGFR inhibitor (compound 4) (Figure 2) was
rationally designed based on the systematic analysis of available
X-ray structures of protein c-KIT, PDGFR, and Abl kinases (Lep-
roult et al., 2011). Starting from the well-known type II kinase
inhibitor imatinib, the methyl piperazine ring in the tail was re-
placed with a chloroacetamide, which resulted in a compound
possessing an IC50 of 788 nM for c-KIT and an IC50 of 1 mM for
PDGFRa, but that lost potency against Abl (IC50 > 20 mM).
Both c-KIT and PDGFRa possess a cysteine residue in the
imatinib tail binding area. Molecular docking to PDGFR demon-
strated that this new inhibitor adopted the same type II binding
mode as observed for imatinib bound to ABL (Cowan-Jacob
et al., 2007), One hydrogen bondwas formed in the hinge binding
area between the pyridine and Cys673 (Figure 3H). Several addi-
tional amino acids including Thr670, Lys623, Glu640, Asp810,
and Ile789 also formed hydrogen bonds with the inhibitor. The
dockingmodel places Cys788within 3 A˚ distance of the chloroa-
cetamide; mass spectrometry has verified that Cys788 can
indeed form a covalent bond with the newly designed inhibitor.
Kinome-wide selectivity profiling showed that this compound
only potently inhibited seven others including JNK1-3, DDR1,
BRAF(V600E), and CSF1R. This irreversible PKI adopts a type
II binding conformation.Chemistry & BiologThe imatinib scaffold has also been elaborated to create the
selective pan-JNK inhibitor, JNK-IN-8 (Zhang et al., 2012).
JNK-IN-8 was discovered to inhibit JNK kinase by broad-based
kinase selectivity profiling of a library of acrylamide kinase inhib-
itors based on the structure of imatinib using the KinomeScan
approach. This discovery was perhaps not entirely unexpected
as imatinib itself possesses a Kd of 5.0 and 3.1 mM for JNK1
and JNK3, respectively. JNK-IN-8 possesses distinct regio-
chemistry of the 1,4-dianiline and 1,3-aminobenzoic acid sub-
structures relative to imatinib and uses anN,N-dimethyl butenoic
acetamide warhead to covalently target Cys154. JNK-IN-8
potently inhibits JNK1, 2, and 3 enzymatic activity with IC50s of
4.7, 18.7, and 1.0 nM, respectively, and inhibits a c-Jun, a direct
phosphorylation substrate of JNK, with an EC50 of 486 nM in
HeLa cells. Broad-based profiling using the chemical proteo-
mics approach termed ‘‘Kinativ’’ (Patricelli et al., 2007) demon-
strated exclusive inhibition of JNK among the approximately
150 kinases detected using the approach. In contrast to imatinib
and the covalent c-KIT/PDGFR inhibitor described above, JNK-
IN-8 adopts an L-shaped type I binding conformation to access
Cys 154 located toward the lip of the ATP-binding site (Figure 3I,
PDB: 3V6S). This finding demonstrates how a kinase inhibitor
class can adopt two completely distinct binding conformations
when binding to different kinases.
A pan-FGFR1, 2, 3, and 4 covalent inhibitor FIIN-1 was devel-
oped starting from the well-established noncovalent inhibitor
PD173074 using a structure-guided approach (Bansal et al.,
2003; Zhou et al., 2010). FIIN-1 is a potent FGFR family covalent
inhibitor that inhibits kinase activity with IC50s of 9.2, 6.2, 11.9,
and 189 nM for FGFR1, 2, 3, and 4 respectively. Kinome-wide
selectivity profiling demonstrated that FIIN-1 is quite selective
and may also bind to FLT1/4 and VEGFR but no other protein
kinases. Molecular modeling suggests that a pair of hydrogen
bonds is present between the amino-pyrimidine core structure
and Ala564 located in the kinase hinge region (Figure 3J). Several
other hydrogen bonds are predicted including a water-mediated
trihydrogen bond involving Lys514, Asp641, and the carbonyl in
the pyrimidine core structure and a hydrogen bond between
Asp641 and the methoxy oxygen in the 2,6-dichloro-3,5-dime-
thoxy aniline side chain. The covalent binding takes place
between Cys486 in the P loop and the acrylamide warhead.
A structure-guided approach was also used to develop an irre-
versible NEK2 PKI named JH295 (Henise and Taunton, 2011).
Starting from a relatively nonselective oxindole-derived inhibitor
SU11652, a propargyl acid warhead was installed to target
Cys22 located in the P loop. JH295 is a potent NEK2 inhibitor
with a biochemical IC50 of 770 nM. Molecular modeling suggestsy 20, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 151
Table 2. Kinases Targeted by Covalent Inhibitors Organized by Kinase Family
AGC CAMK CKI CMGC STE TK TKL Other
RSK None reported None reported GSK-3b, JNK, ERK2 MEK1 EGFR, BTK, VEGFR, FGFR, BMX, KIT, ITK TAK1 IKKb, NEK2
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‘‘hinge’’ residues Glu87 and Cys89 and the oxindole core
(Figure 3K). A water-bridged hydrogen bond involving Lys37
and propargyl amide carbonyl helps to fix the binding conforma-
tion, putting the electrophilic acetylene in close proximity to
Cys22 in the glycine-rich loop (P loop).
A thienylhalomethylketone-based selective irreversible
GSK3-b inhibitor was discovered using high-throughput screen-
ing (Perez et al., 2009). After optimization of the lead compound,
a new GSK3b inhibitor (compound 5) was developed with an
IC50 of 0.5 mM, which exhibited selectivity over other protein
kinases up to a concentration of 10 mM was developed. Molec-
ular modeling suggests that Cys199 in the DFG motif may react
with the chloroacetate to form a covalent bond (Figure 3L).
Several natural products such as celastrol (Lee et al., 2006),
17-acetoxyjolkinolide B (Yan et al., 2008), PGA1 (Rossi et al.,
2000), Parthenolide (Kwok et al., 2001), and Manumycin A (Ber-
nier et al., 2006) have been reported to irreversibly bind IKKb
kinases. Irreversible binding has been indicated using mutagen-
esis or biochemical experiments (Liu et al., 2012a); however,
crystallographic information is not yet available.
Recently, the Taunton laboratory has explored making
‘‘reversible’’ covalent inhibitors of RSK2 (Serafimova et al.,
2012). Here, a 2-cyanoacrylate, which allows reversible addition
of a cysteine thiol to an activated a, b-unsaturated ester, was
introduced onto FMK (Cohen et al., 2005), a scaffold that binds
to the ATP-binding site of RSK2. Competition assays and crys-
tallographic analyses were consistent with covalent bond
formation. Further investigation is required to determine whether
‘‘reversible’’ covalence will help mitigate pharmacology that
derives from covalent modification of unintended targets.
Chemoinformatics Analysis of the Cysteinome
Many protein kinases possess cysteine residues in and around
the ATP-binding site. However, to date only six distinct cysteine
sites have been unequivocally demonstrated to be targeted by
a covalent inhibitor: the cysteine at the lip of the ATP-binding
site targeted by the covalent EGFR, BMX, and BTK inhibitors;
the cysteine in the P loop region targeted by FGFR; the cysteine
in the roof region of the pocket targeting by NEK2 and RSK inhib-
itors; the cysteine immediately preceding the DFGmotif targeted
by VEGFR, ERK2, and GSK3b inhibitors; the cysteine in the
solvent area targeted by JNKs inhibitors; and the cysteine
located in the catalytic loop targeted by inhibitors of c-KIT and
PDGFR. In total, potent and selective inhibitors exist for fewer
than 20 kinases with no examples for two classes of kinases
(Table 2; Figure 4B).
This analysis suggests that currently available irreversible
inhibitors only target a very small fraction of the kinases that
possess potentially reactive cysteine residues. Previously, we
reported that a comprehensive analysis of the literature revealed
accessible cysteines in the ATP-binding pocket of more than 200
protein kinases sites (Zhang et al., 2009). Recently, Leproult et al.
(2011) mined available X-ray crystal structures in the public152 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd Adomain and informatics analyses on different conformations of
the protein kinases revealed there are 27 kinases retaining an
active conformation and bearing 211 cysteine residues that
can be accessible in theory; ten protein kinases retaining the
DFG-out conformation and bearing 127 cysteines; and six
protein kinases retaining the c-helix-out conformation and
bearing 66 cysteines. These studies have provided a good start-
ing point for developing cysteine targeted irreversible kinase
inhibitors. Nonetheless, due to the database limitations, a full
spectrum of the targetable cysteine has yet to be fully mapped.
In order to gain a complete picture of the accessible cysteines
in the kinome and generate a ‘‘kinase cysteinome’’ to facilitate
the systematic exploration for irreversible inhibitors, we per-
formed an informatics study based on the kinome’s primary
sequence alignment with PFAAT, a Java-based multiple
sequence alignment editor and viewer designed for protein
family analysis (Caffrey et al., 2007). Based on the Pfizer in-house
X-ray structure database and RCSB public database, 442
protein kinases were superimposed using CLUSTAW (Thomp-
son et al., 1994) and their ATP-binding sites were evaluated
(atypical and inactive kinases were excluded). Using this
program, 18 spatial cysteine positions were identified (Figure 4)
in 200 unique kinases corresponding to 252 positions in total
(Table 3). This estimation is only approximate as some cysteine
thiols may be inaccessible due to their trajectory or posttransla-
tional modification (nitrosylation, disulphide etc). In addition, it
may also be there are kinases that possess cysteines that are
distant from the ATP site in sequence space but that are in fact
proximal to the ATP site due to the overall conformation of the
kinase.
The 200 kinases identified bearing approachable cysteines are
well distributed among the kinase subfamilies (Table 3; Figure 5).
There are 27 kinases in the TK family, 8 kinases in the TKL family,
34 kinases in the STE family, 16 kinases in the CMGC family, 23
kinases in the CAMK family, 33 kinases in the AGC family, and 48
kinases in the CK1 and other families that possess an ATP site
cysteine. While this primary sequence analysis is complemen-
tary to Leproult’s X-ray-based analysis, experimental validation
will be required to unequivocally establish which kinases can
be targeted by an irreversible PKI.
Strategies to Develop Irreversible Kinase Inhibitors
There are two major approaches for developing novel covalent
inhibitors. The first is to use existing noncovalent inhibitors in
conjunction with structure-guided design. The second is to
create libraries of potentially covalent kinase inhibitors in
conjunction with broad-based kinase profiling to identify new
covalent inhibitors. While we discuss both methods separately,
in practice, both are complementary and are typically used in
an interwoven fashion.
Structure-Guided Design of Covalent Inhibitors
The early reported ‘‘human-inspired’’ covalent inhibitors were
constructed by modifying a known noncovalent inhibitor with
a reactive electrophile at a position predicted to be in proximityll rights reserved
Figure 4. Representative Positions of
Accessible Cysteines in the Active Site
1YVJ, kinase domain used for depiction (cyan,
staurosporine). The various colored circles indi-
cate relative positions of Cys residues depicted on
top of 1YVJ. Red, hinge region; yellow, gatekeeper
and neighboring residues; blue, glycine loop
closer to the ATP site; mauve, flexible region of
glycine loop; green, activation loop (DFG area);
orange, roof region.
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generation covalent EGFR inhibitor derived from PD168393,
the FGFR inhibitor FIIN-1, the VEGFR inhibitor (compound 1),
the NEK2 inhibitor JH295, the RSK inhibitor FMK, and the KIT/
PDGFR inhibitor (compound 4). With the massive expansion in
the number of kinase-ligand complex structures available in
the public domain, there is a wealth of starting points for this
approach. The major challenge with this approach is finding
templates that bind noncovalently in the micromolar range and
that exhibit selectivity among all the kinases with an equivalently
positioned cysteine. Successful covalent bond formation can
then allow selectivity to be achieved relative to all kinases that
do not possess an appropriately positioned cysteine residue. A
further challenge is to obtain a scaffold that presents a suitable
‘‘platform’’ for installation of an electrophilic moiety at the correct
trajectory relative to the nucleophilic cysteine. The less flexibility
there is between the ATP site recognition element and the elec-
trophile, the higher the chances that only a single cysteine
residue will be targeted. In this scenario, the ideal compound is
one whose initial binding mode to the kinase positions the elec-
trophile in a geometry that will allow for rapid bond formation.
The development of FIIN-1 provides a good example of this
structure-guided design approach (Zhou et al., 2010). After a
survey of the known ATP-competitive FGFR inhibitors including
Chir258, Su5402, SU6668, NP603, and PD173074, PD173074
was chosen based upon its potency, selectivity, and availability
of cocrystal structure with FGFR. Inspection of the structure
reveals that Cys486 in the P loop (this residue needed to be
modeled in because it was mutated in the X-ray structure)
of FGFR1 is an approachable nucleophile that is located approx-
imately 10 A˚ away from the pyridine nitrogen of PD173074.
A modeling study suggested that attaching a phenyl group
bearing a meta-acrylamide to the 1-nitrogen of the pyrimidoChemistry & Biology 20, February 21, 2013[4,5]pyridimine might be a reasonable
approach. Compound 6 exhibited good
selectivity when screened against 402
kinases using the KinomeScan approach,
but its cellular activity against FGFR-
dependent cell lines was moderate at
1.5 mM. The loss of 300-fold in cellular
activity relative to PD173074 suggested
that no covalent bond formation was
taking place. Further elaboration involved
elongation of the phenyl warhead by one
more carbon to afford compound 7,
which improved the EC50 to 400 nM.
Further elaboration of the structure by
incorporation of the previously used 2,6-dichloro-3,5-dimethoxyphenyl group to the core scaffold af-
forded FIIN-1, which exhibited an EC50 of 14 nM for inhibiting
FGFR-dependent cell growth. Although FIIN-1 is a covalent
inhibitor, its cellular EC50 is very similar to a corresponding non-
covalent analog (FRIN), which possesses a propyl amide in place
of the acrylamide (Figure 6). This suggests that the scaffold has
sufficiently potent noncovalent binding to achieve the degree of
target engagement necessary to initiate apoptosis in the tel-
FGFR2 transformed Ba/F3 cells used in the study. The major
disadvantage of this structure-guided approach is that it often
fails, which unfortunately goes unreported in the literature.
Selectivity Profiling Data Orientated Design
of Irreversible Inhibitors
A large number of kinase inhibitors are developed based upon
serendipitous observations of cross reactivity observed for es-
tablished kinase inhibitors. Examination of large-scale kinase
profiling data sets has revealed that each compound class has
a particular constellation of kinases that it can efficiently target.
These constellations can range in size from very small such as
lapatinib-related compounds, which primarily only target the
EGFR family, to exceedingly large such as staurosporine-related
compounds. By combining information regarding the constella-
tion of targets that can be addressed noncovalently with the
subset of these targets that may possess an appropriately posi-
tioned cysteine, one can generate new potential covalent inhib-
itors. The development of JNK-IN-8 provides an instructive
example (Zhang et al., 2012). Examination of broad-based
profiling of imatinib reveals that the compounds can bind to
Abl, c-Kit, PDGFR, DDR1, and DDR2 with relatively high affinity
and to JNK1,2,3 and Raf with moderate affinity. Both c-Kit and
PDGFR possess a cysteine that looks like it could be accessed
by replacing the piperazine ring of imatinib, which was realized
by the development of compound 4 (Leproult et al., 2011).ª2013 Elsevier Ltd All rights reserved 153
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Boldface indicates that kinases have been irreversibly targeted by small molecule inhibitors.
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revealed that they are in fact also inhibitors of JNK1,2,3. Exam-
ination of the JNK X-ray structures revealed that Cys116 in
JNK1/2 and Cys154 in JNK3 could be targeted if imatinib used
a binding conformation crystallographically observed for Syk
(PDB: 1XBB). Further structure-activity-guided optimization of
the linker arm between the pyridylpyrimidine ATP-pharmaco-
phore of the compound and the acrylamide resulted in the iden-
tification of JNK-IN-8 (Figure 7).
Our endeavors to identify an irreversible JNK inhibitor started
from the rational design of a type II irreversible inhibitor of KIT
and PDGFR. Kinome-wide selectivity profiling serendipitously
demonstrated that JNKs are one of the most potently inhibited
enzymes by this class of molecule. A key consideration with
this broad-based screening approach is the choice of kinase
profiling technology. Currently, there are several different tech-
nologies available: competitive binding based KinomeScan
developed by DiscoverX (previously Ambit Biosciences) that
can provide more than 450 kinases and related mutants assay
(Fabian et al., 2005; Karaman et al., 2008); activity-based FRET
facilitated SelectScreen technology developed by LifeScience
(previously Invitrogen) that can test more than 220 different154 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd Akinases and mutants (Lebakken et al., 2009); proteomic-
technology-based Kinativ developed by ActivX that can provide
data on up to up to 400 different kinases in a single cell type
depending on the kinase expression (Patricelli et al., 2007); and
the traditional radiometric activity-based assays provided from
multiple commercial and noncommercial sources (Table 4).
The Kinativ approach is a chemical proteomics-based tech-
nology that uses a biotin-tagged acyl phosphate ATP/ADP probe
that can acylate the conserved catalytic lysines and other lysines
located in proximity of the ATP-binding cleft (Patricelli et al.,
2011) By performing competition assays in cells or lysates with
the inhibitor of interest, it is possible to monitor which kinases
are protected from labeling. Because this is one of the only
kinase profiling technologies that can be done following treat-
ment of live cells where the inhibitor is exposed to kinases under
more ‘‘native’’ conditions, it is ideally suited to the profiling of
covalent inhibitors.
Conclusions
Potent and selective kinase inhibitors are highly desirable
reagents for use as probes to pharmacologically interrogate
kinase biology or for use as potential therapeutics. Despite thell rights reserved
Figure 5. Distribution of the Cysteinome in the Kinome Tree
Red dots represent kinases that have been proved to be targeted irreversibly by small molecule inhibitors.
Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 155
Chemistry & Biology
Review
Figure 6. Schematic Representation of
Reversible PKI Scaffold Base Approach to
Develop Irreversible Inhibitors
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goals, there currently exist only a small number of well-charac-
terized covalent inhibitors. However, recently there has been
a resurgence of interest in covalent inhibitors driven by a number
of factors. First is the realization that suitably designed, potent,
and selective inhibitors can achieve clinical efficacy and safety.
Second is the clear potential to use structure-based design
and broad-based selectivity profiling to rapidly generate and
characterize lead compounds against a large number of addi-
tional kinase targets (Serafimova et al., 2012).
Informatic and structural analysis of the cysteinome has iden-
tified approximately 200 distinct kinases with cysteines in close
proximity to the ATP-binding cleft. Furthermore, it is likely that
additional kinases will possess cysteines that are spatially
proximal to the ATP cleft despite being distant in the primary
sequence. Despite this abundance of targets, approximately
only 20 kinases have been reported to be targeted by an irre-
versible inhibitor. There is thus tremendous opportunity for
development of new inhibitors. From a research perspective,
the inhibitors will be valuable tools to help understand the biolog-
ical function of the roughly one-third of the kinome whose func-
tion is poorly understood or for which inhibitors with useful levels
of selectivity do not exist. Cysteine-directed covalent inhibitors156 Chemistry & Biology 20, February 21, 2013 ª2013 Elsevier Ltd All rights reservedhave some key advantages relative to
noncovalent inhibitors when they are to
be used as pharmacological tools for
investigating the biological function of
kinases. Most irreversible inhibitors will
require covalent bond formation with
a particular cysteine residue. Therefore,
it is possible to create a mutant form of
the kinases that is resistant to the effects
of the inhibitor by mutating the reactivecysteine to a serine or an alanine. This inhibitor-resistant mutant
form of the kinase can then be reintroduced to the biological
system of interest by transient or stable expression and the
degree to which it can ‘‘rescue’’ the biological effects elicited
by the covalent inhibitor can be used to establish the functional
selectivity of the compound. This is an extremely powerful
control experiment because the ubiquity of ATP-binding sites
in biological systems always provides for the potential of unan-
ticipated off-target effects for kinase inhibitors. In addition, it is
possible to make noncovalent versions of the inhibitors that
can be used to establish the requirement for covalent bond for-
mation to achieve potent inhibition. From a therapeutic perspec-
tive, estimates suggest 180 kinases may represent attractive
targets for the development of new therapeutics. However, to
date there exist only 11 kinases that are targeted by FDA-
approved kinase inhibitors, which suggests that there exists
considerable opportunity for new covalent inhibitor drugs. The
advantage of covalent inhibitors from a therapeutic standpoint
is the potential to achieve durable target suppression without
the necessity of maintaining high continuous drug exposure.
There are a number of key research directions that would
extend the potential of covalent inhibitors both as pharmacolog-
ical ‘‘tools’’ and as potential therapeutics. The greatest challengeFigure 7. Schematic Representation of
Flowchart for Profiling Data-Based
Approach
Table 4. Commercially Available Kinase Inhibitor Selectivity Profiling Services
Companies Website Technology Kinase Detected
ActivX Biosciences http://www.activx.com Kinativ 400
Bellbrook Labs http://www.bellbrooklabs.com Transcreener
Carna Biosciences http://www.carnabio.com QuickScout 305
DiscoverRx http://www.discoverx.com KinomeScan 451
Invitrogen http://www.invitrogen.com SelectScreen 224
MDS Pharma Services http://www.mdsps.com IMAP 155
Millipore http://www.millipore.com KinEASY FP
MRC Protein Phosphorylation Unit http://www.kinase-screen.mrc.ac.uk (33P-ATP) filter-binding assay 137
ProQinase http://www.proqinase.com ADP Glo 239
Reaction Biology Corporation http://www.reactionbiology.com HotSpot 440
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most obvious way to achieve this is to improve inhibitor potency
through optimization of reversible binding (Ki) and efficiency of
covalent bond formation (kinact). Unlike noncovalent inhibitors,
which can be optimized by monitoring Ki or IC50 values, such
measurements are not accurate means for establishing potency
for covalent inhibitors as they depend upon the incubation time
between the protein and inhibitor. Therefore, considerable
caution should be exercised when comparing the IC50s of
different irreversible inhibitors, and a more appropriate method
to assess inhibition is the ‘‘specificity constant’’ kinact/Ki– the
larger this value, the more efficient the molecule is at inhibiting
the protein, as it takes into account both the initial equilibrium
of the noncovalent complex and the rate of inactivation through
the formation of a covalent bond (Schirmer et al., 2006). Unfortu-
nately, there is a paucity of such information in the scientific liter-
ature for irreversible inhibitors.
For example, these values can be used to delineate structure-
activity (and selectivity) relationships across a range of covalent
inhibitors. Prospectively then, optimization of both binding
affinity and the resulting rate of reaction with the target residue
in the kinase will ultimately lead to the development of highly effi-
cient, and selective, inhibitors. When the covalent inhibitors are
used in cellular assays or in vivo, further considerations become
important. First, the cellular environment possesses a large
number of potentially reactive cysteine residues and modifica-
tion of the desired target always occurs competitively with these
additional off-targets. A second consideration is that a covalent
inhibitor only inactivates the enzyme-target until protein syn-
thesis generates newprotein. Proteins are synthesized at a range
of rates, and therefore it is important to determine the time it
takes to recover protein function after exposure to the covalent
inhibitor (Johnson et al., 2010; Singh et al., 2011).
A second technological breakthough would be to develop new
classes of ‘‘electrophilic warheads’’ that are specifically ‘‘tuned’’
to a thiol based on its pKa. For example, it maybe possible to
develop ‘‘mechanism-based’’ covalent inhibitors where the elec-
trophile is only unleashed upon binding the kinase target. This
could be achieved by designing an electrophile whose reactivity
is enhanced due to a protein-induced conformational change to
the inhibitor. Another significant challenge is to devise methods
to better annotate the subset of the proteome that is reactive to
a given covalent inhibitor class (i.e., the ‘‘protein reactome’’) andChemistry & Biologto establish targets associated with toxicology in various organs.
We anticipate that a large number of new covalent kinase inhib-
itors will be developed in the near future that will provide the
means to obtain new therapeutic insights.
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